Pan-Asia Index Rebalances/ Events/ Delta One, Periscope Analytics

Brian Freitas

Pan-Asia Index Rebalances/ Events/ Delta One

Periscope Analytics

Periscope Analytics focuses on event-driven trades across Asia Pacific and provides comprehensive, timely and systematic coverage of index changes to major Asia Pacific indices in a structured manner.

The analysis includes forecasted inclusions and exclusions to all major Asian indices that have significant amount of tracking assets, including estimates of passive buy/sell flow on the stocks. The service also provides commentary and impact of market consultations, ground rule changes, and other events (IPOs, spin-offs, M&A) that could lead to index changes and passive flow.

Periscope Analytics works with multi-strategy hedge funds, proprietary trading firms, stat arb trading groups and long-only investors that invest and trade in the Asia Pacific region with the data being used to trade index rebalances, avoid pre-positioning and passive flow, and to time entry into and exit from stocks.

Event-Driven Trades Across Asia Pacific

Index Rebalance

Caliway Biopharmaceuticals / Index Rebalance

<ul>
<li>
<a href="https://www.smartkarma.com/entities/caliway-biopharmaceuticals-co-ltd" target="_blank" data-smartkarma-citation="entities:44038:1" rel="noopener">Caliway Biopharmaceuticals (6919 TT)</a> and <a href="https://www.smartkarma.com/entities/king-slide-works-co-ltd" target="_blank" data-smartkarma-citation="entities:7130:1" rel="noopener">King Slide Works (2059 TT)</a> replace <a href="https://www.smartkarma.com/entities/taiwan-cement" target="_blank" data-smartkarma-citation="entities:19736:1" rel="noopener">Taiwan Cement (1101 TT)</a> and <a href="https://www.smartkarma.com/entities/pharmaessentia-corp" target="_blank" data-smartkarma-citation="entities:16461:1" rel="noopener">Pharmaessentia Corp (6446 TT)</a> in the Yuanta/P-Shares Taiwan Top 50 ETF in September.</li>
<li>
<a href="https://www.smartkarma.com/entities/caliway-biopharmaceuticals-co-ltd" target="_blank" data-smartkarma-citation="entities:44038:1" rel="noopener">Caliway Biopharmaceuticals (6919 TT)</a> and <a href="https://www.smartkarma.com/entities/king-slide-works-co-ltd" target="_blank" data-smartkarma-citation="entities:7130:1" rel="noopener">King Slide Works (2059 TT)</a> were added to a global index in August and that resulted in a large percentage of float being bought.</li>
<li>
<a href="https://www.smartkarma.com/entities/caliway-biopharmaceuticals-co-ltd" target="_blank" data-smartkarma-citation="entities:44038:1" rel="noopener">Caliway Biopharmaceuticals (6919 TT)</a> will be added to another global index in September and that will further reduce the real float of the stock.</li>
</ul>



Caliway Biopharmaceuticals (6919 TT) and King Slide Works (2059 TT) replace Taiwan Cement (1101 TT) and Pharmaessentia Corp (6446 TT) in the Yuanta/P-Shares Taiwan Top 50 ETF in September.

Caliway Biopharmaceuticals (6919 TT) and King Slide Works (2059 TT) were added to a global index in August and that resulted in a large percentage of float being bought.

Caliway Biopharmaceuticals (6919 TT) will be added to another global index in September and that will further reduce the real float of the stock.


Taiwan Top 50 ETF Rebalance: Another Inclusion for Caliway Biopharma & King Slide

<ul>
<li>There could be 2 changes for the Yuanta/P-Shares Taiwan Top 50 ETF in September - both changes are high probability.</li>
<li>
<a href="https://www.smartkarma.com/entities/caliway-biopharmaceuticals-co-ltd" target="_blank" data-smartkarma-citation="entities:44038:1" rel="noopener">Caliway Biopharmaceuticals (6919 TT)</a> and <a href="https://www.smartkarma.com/entities/king-slide-works-co-ltd" target="_blank" data-smartkarma-citation="entities:7130:1" rel="noopener">King Slide Works (2059 TT)</a> are being added to a global index at the close today and are potential inclusions to the ETF in September.</li>
<li>
<a href="https://www.smartkarma.com/entities/caliway-biopharmaceuticals-co-ltd" target="_blank" data-smartkarma-citation="entities:44038:1" rel="noopener">Caliway Biopharmaceuticals (6919 TT)</a> will also be added to another global index at the close on 19 September, so more passive inflows for the stock. Reversion thereafter?</li>
</ul>


There could be 2 changes for the Yuanta/P-Shares Taiwan Top 50 ETF in September - both changes are high probability.

Caliway Biopharmaceuticals (6919 TT) and King Slide Works (2059 TT) are being added to a global index at the close today and are potential inclusions to the ETF in September.

Caliway Biopharmaceuticals (6919 TT) will also be added to another global index at the close on 19 September, so more passive inflows for the stock. Reversion thereafter?


Taiwan Top 50 ETF Rebalance Preview: Hat Trick for Caliway Biopharma?

<ul>
<li>There could be 4 constituent changes for the Yuanta/P-Shares Taiwan Top 50 ETF in December as positioning for buying by one set of index trackers pushes stocks into other indices.</li>
<li>There will be passive inflows in some of the forecast adds week after next and the flows from these index trackers will come a few weeks later.</li>
<li>With large AUMs tracking the dividend indices, stocks that have moved up a lot now have low dividend yields and there could be opposite flows from those index trackers.</li>
</ul>


There could be 4 constituent changes for the Yuanta/P-Shares Taiwan Top 50 ETF in December as positioning for buying by one set of index trackers pushes stocks into other indices.
There will be passive inflows in some of the forecast adds week after next and the flows from these index trackers will come a few weeks later.
With large AUMs tracking the dividend indices, stocks that have moved up a lot now have low dividend yields and there could be opposite flows from those index trackers.


Taiwan Top 50 ETF Rebalance Preview: Plenty of Big Overlapping Flows Coming Up

Global Healthcare Analyst

Tina Banerjee

Thematic (Sector/Industry)

<ul>
<li>Takeda has dropped AstraZeneca-partnered antibody drug candidate from its pipeline. Eisai and Merck are closing late-stage trial of Lenvima plus Keytruda in hepatocellular carcinoma on disappointing result.</li>
<li>Wuxi AppTec sharpens CRDMO business by selling its China-based clinical research subsidiaries. FDA has designated Celltrion’s Stoboclo and Osenvelt as interchangeable biosimilars to the reference products Prolia and Xgeva, respectively.</li>
<li>CSL is delaying demerger of CSL Seqirus ‘to maximise shareholder value.’ PharmaEssentia has filed for the additional indication of Besremi for Essential Thrombocythemia (ET) with the FDA.</li>
</ul>


Takeda has dropped AstraZeneca-partnered antibody drug candidate from its pipeline. Eisai and Merck are closing late-stage trial of Lenvima plus Keytruda in hepatocellular carcinoma on disappointing result.
Wuxi AppTec sharpens CRDMO business by selling its China-based clinical research subsidiaries. FDA has designated Celltrion’s Stoboclo and Osenvelt as interchangeable biosimilars to the reference products Prolia and Xgeva, respectively.
CSL is delaying demerger of CSL Seqirus ‘to maximise shareholder value.’ PharmaEssentia has filed for the additional indication of Besremi for Essential Thrombocythemia (ET) with the FDA.


APAC Healthcare Weekly (November 2) – Takeda, Eisai, Wuxi AppTec, Celltrion, CSL, PharmaEssentia

Index Rebal Trades & Special Situations, Quiddity Advisors

Janaghan Jeyakumar, CFA

Index Rebal Trades & Special Situations

Quiddity Advisors

Pan-Asia Catalysts/Events

Hua Nan Financial Holdings Co Ltd. / Index Rebalance

<ul>
<li>The index changes for the T50/100 index family and the TDIV index were confirmed after market close on Friday 5th September 2025.</li>
<li>There will be two ADD/DEL for T50, five separate ADDs/DELs for T100, and no changes for TDIV.</li>
<li>All of these are exactly in line with our final expectations.</li>
</ul>


The index changes for the T50/100 index family and the TDIV index were confirmed after market close on Friday 5th September 2025.
There will be two ADD/DEL for T50, five separate ADDs/DELs for T100, and no changes for TDIV.
All of these are exactly in line with our final expectations.


Quiddity T50/100/DIV Sep25 Results: 100% Hit Rate; M&A DEL King's Town to Trigger Intra-Review Flows

Taiwan

Caliway Biopharmaceuticals Co., Ltd. focuses on breakthrough medical aesthetics and inflammatory medicine discovery of small molecule therapeutics. The Company develops CBL-514 to treat subcutaneous fat. Caliway Biopharmaceuticals conducts businesses across worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Caliway Biopharmaceuticals (6919 TT)

Taiwan Top 50 ETF Rebalance: Another Inclusion for Caliway Biopharma & King Slide

Caliway Biopharma and King Slide are adds at the close on 19 Sep. Both stocks were added to a global index end August and Caliway has another...

Brian Freitas

Taiwan Top 50 ETF Rebalance Preview: Hat Trick for Caliway Biopharma?

There could be 2 changes for the ETF in Sep. Caliway and King Slide are inclusions to a global index at the close today. Passive trackers of...

Brian Freitas

Taiwan Top 50 ETF Rebalance Preview: Plenty of Big Overlapping Flows Coming Up

We currently forecast 4 changes for the ETF in Dec. That could increase to 5. Multiple stocks will have same-way flow from other index trackers...

Brian Freitas

APAC Healthcare Weekly (November 2) – Takeda, Eisai, Wuxi AppTec, Celltrion, CSL, PharmaEssentia

Takeda and Eisai witnessed clinical trials setback. Wuxi AppTec is selling China-based CRO subsidiaries. CSL is delaying demerger of CSL Seqirus....

Tina Banerjee

Quiddity T50/100/DIV Sep25 Results: 100% Hit Rate; M&A DEL King's Town to Trigger Intra-Review Flows

We expect US$866mn one-way flows for the TDIV index. There are few high-impact names with more than 3x ADV to trade. Some of the high-impact names...

Janaghan Jeyakumar, CFA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)